Report interim data from the OLE study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Jun 2024
- Due
- 31 Dec 2024
- Delivered
- December 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“interim data expected in Q4 2024”
What we found
Evidence strength A What the grades mean
The company reported positive initial data from its ongoing OLE study in December 2024, fulfilling the commitment to report interim data by the end of Q4 2024.
-
A Larimar Therapeutics, Inc. 10-K filed 2025-03-24
“In December 2024, we reported positive initial data from our ongoing OLE study.” ✓ confirmed on the page
Market reaction: the shares moved -12.2% against the S&P 500 over the three sessions around the disclosure (21 Mar 2025 to 26 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 10 Jun 2024
Deadline 31 Dec 2024 (“Q4 2024”) · wording expected
-
Version 2 · stated 10 Jan 2025
Deadline 30 Jun 2025 (“mid-2025”) · target 50 mg · wording expected
“50 mg data expected mid-2025”
-
Version 3 · stated 24 Mar 2025
Deadline 30 Sep 2025 (“Sept 2025”) · target 50 mg · wording expected
“Topline 50 mg data from OLE study planned for Sept 2025”
-
Version 4 · stated 23 Jun 2025
Deadline 30 Sep 2025 (“in September 2025”) · target 40 participants · wording expected
“OLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Interim data from OLE study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-002998 · Corrections policy